— News and commentary from the endocrinology world
August 4, 2026
• 2 min read
The American Diabetes Association (ADA) asked for patience as its Audit and Governance Committee reviews the incident at this year's annual meeting -- when five prominent experts were removed by police -- and prepares recommendations on the organization's response.
Once-weekly somapacitan (Sogroya) was noninferior to daily growth hormone injections for boosting growth in treatment-naïve girls with Turner syndrome while maintaining insulin-like growth factor 1 concentrations within a similar range, according to a phase III trial. (Journal of Clinical Endocrinology & Metabolism)
